Financial Architects, Inc Incyte Corp Transaction History

Financial Architects, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$85.07 - $109.69 $17,014 - $21,938	-200 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $14,608 - $19,144	200 New	200 $17,000
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $14,704 - $17,740	-200 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$63.56 - $88.17 $12,712 - $17,634	200 New	200 $17,000
Q1 2019 May 03, 2019	SELL	$63.56 - $88.17 $12,712 - $17,634	-200 Closed	0 $0
Q3 2018 Oct 29, 2018	SELL	$61.75 - $74.23 $6,175 - $7,423	-100 Reduced 33.33%	200 $14,000
Q2 2018 Aug 03, 2018	BUY	$60.85 - $83.98 $6,085 - $8,398	100 Added 50.0%	300 $20,000
Q1 2018 Apr 23, 2018	SELL	$83.06 - $100.98 $13,704 - $16,661	-165 Reduced 45.21%	200 $17,000
Q4 2017 Feb 12, 2018	BUY	$93.56 - $116.6 $15,437 - $19,239	165 Added 82.5%	365 $34,000
Q3 2017 Nov 01, 2017	BUY	$109.15 - $138.27 $21,830 - $27,654	200	200 $23,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.